Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ferrocalm is a probiotic food supplement containing the proprietary bacterial strain *Streptococcus thermophilus* FX856. Developed by Ferryx, a spin-out from the University of Bristol, this live biotherapeutic is specifically designed to survive and remain active in the challenging environment of an inflamed gut, even in the presence of iron. It is marketed to support gut health and alleviate symptoms of Irritable Bowel Syndrome (IBS), particularly during periods of stress. The product was launched in the UK in 2022 as a dietary supplement rather than a regulated pharmaceutical drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ferrocalm.